A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Yutaka Niihara, MD, MPH
Chairman and CEO
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
31 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of South Alabama Medical Center
Mobile, Alabama, United States
- Phoenix Children'S Hospital Center for Cancer and Blood Disorders
Phoenix, Arizona, United States
- Kaiser Permanente
Inglewood, California, United States
- Children'S Hospital & Research Center at Oakland
Oakland, California, United States
- Children'S Hospital of Orange County
Orange, California, United States
- Harbor-Ucla Medical Center
Torrance, California, United States
- University of Denver School of Medicine Sickle Cell Treatment & Research Center
Aurora, Colorado, United States
- Howard University Hospital & Howard University
Washington D.C., District of Columbia, United States
- University of Florida
Gainesville, Florida, United States
- All Children'S Hospital
St. Petersburg, Florida, United States
- Children'S Healthcare of Atlanta at Egleston/emory University
Atlanta, Georgia, United States
- University of Illinois at Chicago
Chicago, Illinois, United States
- University of Louisville School of Medicine
Louisville, Kentucky, United States
- Sickle Cell Center of S. Louisiana, Tulane University School of Medicine
New Orleans, Louisiana, United States
- Johns Hopkins University
Baltimore, Maryland, United States
- Boston University Medical Center
Boston, Massachusetts, United States
- Children'S Hospital of Michigan
Detroit, Michigan, United States
- University of Mississippi Medical Center
Jackson, Mississippi, United States
- Children'S Mercy Hospitals and Clinics
Kansas City, Missouri, United States
- Children'S Specialty Center of Nevada
Las Vegas, Nevada, United States
- Comprehensive Cancer Center of Nevada
Las Vegas, Nevada, United States
- Cooper University Hospital
Camden, New Jersey, United States
- Brookdale University Hospital and Medical Center
Brooklyn, New York, United States
- Interfaith Medical Center
Brooklyn, New York, United States
- New York Methodist Hospital - Sc/thalassemia Program
Brooklyn, New York, United States
- Suny - Downstate Medical Center
Brooklyn, New York, United States
- the Brooklyn Hospital Center
Brooklyn, New York, United States
- Bronx Lebanon Hospital
The Bronx, New York, United States
- Presbyterian Blume Pediatric Hematology-Oncology Clinic
Charlotte, North Carolina, United States
- University of Tennessee Cancer Institute
Memphis, Tennessee, United States
- Virginia Commonwealth University
Richmond, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2010
- Primary completion
- 31 Mar 2014
- Completion
- 31 Mar 2014
- Last update posted
- 19 Aug 2020
- Registered enrollment
- 230
- Registry id
- NCT01179217
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.